Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Lexicon Pharmaceuticals Inc (LXRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.48+1.37%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LXRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain access to $100M loan facility | A supporting condition in Lexicon Pharmaceuticals Inc's published investment case. The stated target is Maintain borrowing capacity up to $100M. | Intact | Loan facility is withdrawn or materially reduced | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not an established earnings compounder. The long-term thesis is in a watch state: management has advanced key studies and strengthened cash resources, while recent financial performance remains weak and risk is elevated.
The valuation model signals a durable premium versus peers, while the expectations gap is high and the priced-in tag is unjustified. That points to a valuation that may assume lasting strength without enough support from current financial results; confidence in this assessment is medium.
Near term, results may remain uneven: 2026-Q1 revenue included a milestone payment, while 2026-Q2 revenue came mainly from INPEFA sales and was much lower. Management completed SONATA-HCM Phase 3 enrollment and is pursuing a ZYNQUISTA NDA resubmission, with topline data expected in 2027-Q1; cash and investments also rose after equity financing and a loan facility. The business remains loss-making, and the evidence on near-term execution risk is limited.
The multi-year view hinges on clinical and regulatory milestones arriving on management’s stated timelines and on product sales or licensing becoming a more dependable revenue source. A guidance cut would be a negative signal, while continued strength among large healthcare companies could support the sector backdrop; weaker employment data could weigh on cyclical healthcare names.
Over the next 1 to 3 years, LXRX’s thesis depends on translating clinical progress and added funding into more durable commercial progress. Weak results and a valuation premium leave little evidence that the thesis is already established. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating losses improved sharply, from -$14.78M to about -$1M. |
| Under Pressure |
| operating loss worsens below -$3M per quarter |
Operating income: $-26.54M FY2026-Q2; GAAP. Published target: operating loss >= -$1M per quarter. Target period is not explicitly aligned with this observation. Aug 6, 2026-26,540,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Research and Development (R&D) Expenses: Research and development expenses for the second quarter of 2026 increased to $17.4 million from $15.7 million for the corresponding period in 2025, reflecting higher external research expense in 2026 related to the Company’s ongoing SONATA-HCM Phase 3 clinical trial.” “Net Loss: Net loss for the second quarter of 2026 was $31.8 million, or $0.07 per share, as compared to net income of $3.3 million, or $0.01 per share, in the corresponding period in 2025.” Net income was $-31.775 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Sustain revenue growth above consensus | A primary condition in Lexicon Pharmaceuticals Inc's published investment case. The stated target is >= $21M quarterly revenue. | Broken | quarterly revenue falls below $15M | Revenue: $692,000 FY2026-Q2; GAAP. Published target: >= $21M quarterly revenue. Target period is not explicitly aligned with this observation. Aug 6, 2026692,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.21 → $-0.21 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.21 | $20,153,249 | 3 / 3 |
| 2026-07-25 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-07-26 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-07-27 | $-0.21 | $20,153,249 | 3 / 3 |
| 2026-07-28 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-07-29 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-07-30 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-07-31 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-08-01 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-02 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-08-03 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-08-04 | $-0.21 | $20,153,250 | 5 / 5 |
| 2026-08-05 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-06 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-07 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-08 | $-0.21 | $23,466,560 | 5 / 4 |
| 2026-08-09 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-10 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-12 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-13 | $-0.19 | $10,266,560 | 4 / 4 |
| 2026-08-14 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-15 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-16 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-17 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-18 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-19 | $-0.20 | $20,153,249 | 3 / 3 |
| 2026-08-20 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-21 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-22 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-23 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-24 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-25 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-26 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-27 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-28 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-29 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-30 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-08-31 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-01 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-02 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-03 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-04 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-05 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-06 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-07 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-08 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-09 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-10 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-11 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-12 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-13 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-14 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-15 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-16 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-17 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-18 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-19 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-20 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-21 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-22 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-23 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-24 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-25 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-26 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-27 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-28 | $-0.20 | $19,913,249 | 3 / 3 |
| 2026-09-29 | $-0.21 | $16,934,374 | 3 / 3 |
| 2026-09-30 | $-0.21 | $16,934,374 | 3 / 3 |
| 2026-10-01 | $-0.21 | $16,934,374 | 3 / 4 |
| 2026-10-02 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-03 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-04 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-05 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-06 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-07 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-08 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-09 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-10 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-11 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-12 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-13 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-14 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-15 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-16 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-17 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-18 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-19 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-20 | $-0.21 | $16,927,707 | 4 / 4 |
| 2026-10-21 | $-0.21 | $16,927,707 | 4 / 4 |
| 2026-10-22 | $-0.21 | $16,927,707 | 4 / 4 |
| 2026-10-23 | $-0.21 | $16,927,707 | 4 / 4 |
| 2026-10-24 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-25 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-26 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-27 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-28 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-29 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-30 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-10-31 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-11-01 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-11-02 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-11-03 | $-0.21 | $16,934,374 | 4 / 4 |
| 2026-11-04 | $-0.21 | $16,934,374 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.